WO2012046943A3 - 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체 - Google Patents

재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체 Download PDF

Info

Publication number
WO2012046943A3
WO2012046943A3 PCT/KR2011/004693 KR2011004693W WO2012046943A3 WO 2012046943 A3 WO2012046943 A3 WO 2012046943A3 KR 2011004693 W KR2011004693 W KR 2011004693W WO 2012046943 A3 WO2012046943 A3 WO 2012046943A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
recombinant adenovirus
regulating sequence
delivery system
gene expression
Prior art date
Application number
PCT/KR2011/004693
Other languages
English (en)
French (fr)
Other versions
WO2012046943A2 (ko
Inventor
윤채옥
윤아름
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to US13/878,266 priority Critical patent/US9689000B2/en
Priority to JP2013532709A priority patent/JP5807236B2/ja
Priority to EP11830829.5A priority patent/EP2657339B1/en
Priority to CN201180053329.9A priority patent/CN103314107B/zh
Publication of WO2012046943A2 publication Critical patent/WO2012046943A2/ko
Publication of WO2012046943A3 publication Critical patent/WO2012046943A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 HRE, E2F 및 TERT의 조합으로 이루어진 유전자발현 조절서열 및 이를 이용한 선택적 종양세포 살상능이 크게 개선된 유전자 전달체, 특히 재조합 아데노바이러스에 관한 것이다. 또한, 상기 재조합 아데노바이러스를 포함하는 약제학적 항종양 조성물에 관한 것이다. 본 발명의 재조합 아데노바이러스는 본 발명 특유의 유전자발현 조절서열에 의하여 종양 특이적으로 복제가 조절됨으로서 선택적 종양세포 살상능 또는 고사능이 개선된 효과를 발휘하며, 특히 저산조 조건에서 크게 향상된 항종양 효과를 나타낸다. 또한, 암세포 내에서 재조합 아데노바이러스의 특이적 발현으로 체내에서의 안정성이 증대되어 더욱 개선된 항종양 효과를 유도할 수 있다.
PCT/KR2011/004693 2010-10-08 2011-06-28 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체 WO2012046943A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/878,266 US9689000B2 (en) 2010-10-08 2011-06-28 Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence
JP2013532709A JP5807236B2 (ja) 2010-10-08 2011-06-28 組み換えられた遺伝子発現調節配列を有する腫瘍特異的発現の改善された遺伝子伝達システム
EP11830829.5A EP2657339B1 (en) 2010-10-08 2011-06-28 Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence
CN201180053329.9A CN103314107B (zh) 2010-10-08 2011-06-28 具有重组的基因表达调控序列的肿瘤特异性表达得到改善的基因运载体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100098498A KR101232123B1 (ko) 2010-10-08 2010-10-08 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
KR10-2010-0098498 2010-10-08

Publications (2)

Publication Number Publication Date
WO2012046943A2 WO2012046943A2 (ko) 2012-04-12
WO2012046943A3 true WO2012046943A3 (ko) 2012-05-31

Family

ID=45928176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004693 WO2012046943A2 (ko) 2010-10-08 2011-06-28 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체

Country Status (6)

Country Link
US (1) US9689000B2 (ko)
EP (1) EP2657339B1 (ko)
JP (1) JP5807236B2 (ko)
KR (1) KR101232123B1 (ko)
CN (1) CN103314107B (ko)
WO (1) WO2012046943A2 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070197A1 (en) * 2015-10-19 2017-04-27 Immunolight, Llc X-ray psoralen activated cancer therapy (x-pact)
US10441810B2 (en) 2007-04-08 2019-10-15 Immunolight, Llc X-ray psoralen activated cancer therapy (X-PACT)
PL2908865T3 (pl) 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
JP6566214B2 (ja) * 2014-05-28 2019-08-28 国立大学法人 岡山大学 Ｒｅｉｃ遺伝子を発現する制限増殖型アデノウイルス
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
KR102543671B1 (ko) * 2016-03-14 2023-06-16 진메디신 주식회사 전자기장에 의한 항종양 효과가 증대된 아데노바이러스-pcion 복합체
WO2018062740A1 (ko) * 2016-09-30 2018-04-05 재단법인 차세대융합기술연구원 Smad3 epsm 단백질을 발현하는 종양 특이적 종양용해적 아데노바이러스
EP3725875A4 (en) * 2017-12-13 2021-10-06 Genemedicine Co., Ltd. RECOMBINANT ADENOVIRUS AND STEM CELLS WITH IT
GB201902277D0 (en) * 2019-02-19 2019-04-03 King S College London Therapeutic agents
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
EP3987028A4 (en) * 2019-06-21 2023-07-19 Kernal Biologics, Inc. MODIFIED ONCOSELECTIVE PROTEIN EXPRESSION
WO2021011826A1 (en) * 2019-07-16 2021-01-21 Coastar Therapeutics Inc. Process of making membrane lipid coated nanoparticles
JP7316711B2 (ja) * 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド 脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
WO2023008925A1 (ko) * 2021-07-29 2023-02-02 주식회사 리보퓨틱스 융합 프로모터, 이를 포함하는 재조합 벡터 및 이를 이용하는 간암 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068307A1 (en) * 2000-03-24 2003-04-10 De-Chao Yu Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7575919B2 (en) * 1998-09-10 2009-08-18 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
EP1421947A1 (en) 1992-07-22 2004-05-26 The Trustees Of Princeton University p53 vaccine
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR2740344B1 (fr) 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
RU2007137122A (ru) * 2005-03-09 2009-04-20 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем (Us) НОВЫЙ ПРОМОТОР hTMC И ВЕКТОРЫ ДЛЯ ОПУХОЛЕСЕЛЕКТИВНОЙ И ВЫСОКОЭФФЕКТИВНОЙ ЭКСПРЕССИИ ТЕРАПЕВТИЧЕСКИХ ПРОТИВОРАКОВЫХ ГЕНОВ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575919B2 (en) * 1998-09-10 2009-08-18 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20030068307A1 (en) * 2000-03-24 2003-04-10 De-Chao Yu Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAI, Q. ET AL.: "Kaposi' s Sarcoma-Associated Herpesvirus Latent Protein LANA Interacts with HIF-la to Upregulate RTA Expression during Hypoxia: Latency Control under Low Oxygen Conditions", JOURNAL OF VIROLOGY, vol. 80, no. 16, 31 August 2006 (2006-08-31), pages 1308 - 1312, XP055106398 *
PAPADAKIS E.D. ET AL.: "Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy", CURRENT GENE THERAPY, vol. 4, no. 1, 31 March 2004 (2004-03-31), pages 89 - 113, XP009159935 *

Also Published As

Publication number Publication date
JP5807236B2 (ja) 2015-11-10
US9689000B2 (en) 2017-06-27
US20130323206A1 (en) 2013-12-05
EP2657339A4 (en) 2014-05-07
EP2657339B1 (en) 2015-08-19
CN103314107A (zh) 2013-09-18
EP2657339A2 (en) 2013-10-30
WO2012046943A2 (ko) 2012-04-12
KR20120036688A (ko) 2012-04-18
KR101232123B1 (ko) 2013-02-12
CN103314107B (zh) 2015-11-25
JP2013543386A (ja) 2013-12-05

Similar Documents

Publication Publication Date Title
WO2012046943A3 (ko) 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
CR20200571A (es) Moléculas de únion contra bcma y usos de las mismas
WO2012058673A3 (en) Enhanced cancer treatment and monitoring using recombinant vectors
WO2011070440A3 (en) Oncolytic rhabdovirus
WO2012107908A3 (en) Nts-polyplex nanoparticles system for gene therapy of cancer
BR112015008612A2 (pt) métodos de tratamento utilizando adenovirus
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
IN2014DN10390A (ko)
WO2009095261A3 (en) Vaccine compositions
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
MY170604A (en) Inhibitors of apoptosis and uses thereof
WO2012064146A3 (ko) Ｇｋｎ １을 함유하는 항암용 조성물
WO2014041088A3 (en) Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
NZ705124A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
WO2009101149A3 (en) Anti-tumour effective paramyxovirus
WO2009051659A3 (en) Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
WO2011109422A3 (en) Compositions and methods for the treatment of cancer
WO2009078977A3 (en) Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
WO2012151279A3 (en) Induction of il-12 using immunotherapy
BR112013003989A2 (pt) características e propriedades citolíticas de células expressando th1
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2012173677A3 (en) Anticancer therapeutic agents
WO2014047546A3 (en) Use of mir-494 to modulate trail-induced apoptosis through bim down-regulation
WO2010117287A3 (en) A virus-like particle vector for delivery of pharmaceutical agents, a process for the manufacture thereof, its uses and a pharmaceutical composition.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11830829

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013532709

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13878266

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011830829

Country of ref document: EP